Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

SMMT Summit Therapeutics Inc

4,4018

-0,1082 (-2,40%)

Nach Börsenschluss

Zuletzt aktualisiert: 23:44:31

Verzögert um 15 Minuten

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more Summit Therapeutics Charts.

Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more Summit Therapeutics Charts.

News Summit Therapeutics Inc

Form 8-K - Current report
Montag 13 Mai 2024 (4 Tage vor) • Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Montag 13 Mai 2024 (4 Tage vor) • Edgar (US Regulatory)

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
Mittwoch 1 Mai 2024 (2 Wochen vor) • Business Wire

Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
Mittwoch 24 April 2024 (3 Wochen vor) • Business Wire

Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
Donnerstag 11 April 2024 (1 Monat vor) • Business Wire

Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
Mittwoch 10 April 2024 (1 Monat vor) • Business Wire

Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
Freitag 22 März 2024 (2 Monate vor) • Business Wire

Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
Donnerstag 14 März 2024 (2 Monate vor) • Business Wire

Form 8-K - Current report
Dienstag 5 März 2024 (2 Monate vor) • Edgar (US Regulatory)

Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
Dienstag 5 März 2024 (2 Monate vor) • Business Wire

Form 8-K - Current report
Dienstag 20 Februar 2024 (3 Monate vor) • Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933
Dienstag 20 Februar 2024 (3 Monate vor) • Edgar (US Regulatory)

Weitere Summit Therapeutics Inc News-Artikel

Deutsche Telekom (QX)

JP Morgan Chase

Deutsche Lufthansa

BNP Paribas (QX)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen